Secure CheckoutPersonal information is secured with SSL technology.
Free ShippingFree global shipping
No minimum order.
Fibroblast Growth Factor 23 describes how FGF23 was initially identified as a bone-derived factor targeting the kidney. As such, sections in this comprehensive book cover exciting research that shows that different FGF23 effects require distinct signaling receptors and mediators that differ among target tissues, cover FGF23 initially identified as a bone-derived factor targeting the kidney, look at FGF23 as a regulator of phosphate metabolism and beyond, and cover research on novel concepts of FGF receptor signaling. Additional sections cover biochemistry, pharmacology and nephrology, making this book an ideal reference source on FGF23.
- Provides a comprehensive collection of chapters on the diversity of FGF23's actions
- Highlights truly translational topics, from molecular signaling to physiology and mechanism of disease, discussing cell culture and animal models to study FGF23
- Describes FGF23’s potential in the clinical setting as a biomarker or even drug target
- Presents leaders in the field who cover a wide spectrum of research backgrounds and expertise, including clinical and basic scientists who specialize in diseases, endocrinology, genetics, protein biochemistry, cell biology and physiology
Biomedical researchers and research clinicians in the field researching FGF23; basic scientists in physiology, biochemistry and genetics, clinicians such as nephrologists, bone and mineral researchers and endocrinologists
1. The discovery of FGF23 – a historic view: genetic disorders of hypo- and hyperphosphatemia
Michael J. Econs and Farah Laith Al Sabie
2. FGF23 – an established master regulator of phosphate metabolism
3. FGF23 – more than a phosphaturic hormone
Reinhold G. Erben
4. The regulation of FGF23 production in bone and outside of bone
5. Klotho-dependent actions of FGF23 - targets, signal transduction and cellular effects
6. Klotho-independent actions of FGF23 - targets, signal transduction and cellular effects
Alexander Grabner and John Musgrove
7. The experimental detection of FGF23 responsiveness and effects
Farzana Perwad and Daniela Egli-Spichtig
8. FGF23 and bone disease
Katherine Wesseling Perry
9. FGF23 and kidney disease
Anna Jovanovich, Chang Huei Chen and Taylor Struemph
10. FGF23 and heart and vascular disease
11. FGF23 and inflammation, anemia, and iron
Mark R. Hanudel
12. FGF23 and infectious diseases
Justine Bacchetta and Martin Hewison
13. FGF23 and lung disease
14. FGF23 and neuro-cognitive disorders
Carlos Cesar Faraco and Clinton Wright
15. FGF23 as a drug target
Erik A. Imel
16. FGF23 – resolved issues, remaining controversies and future questions – a clinician’s perspective
Gunnar Henrik Heine
17. Klotho – the discovery of the FGF23 co-receptor
18. Klotho – an FGF23-independent hormone
Chou-Long Huang and Orson W. Moe
19. Klotho and aging phenotypes
20. αKlotho gene and protein measurements in humans and their role as a clinical biomarker of disease
21. Structural Basis of FGF23 Hormone Signaling
22. Klotho – open questions, controversies and future perspectives
23. The crosstalk between phosphate, FGF23 and klotho in the regulation of tissue homeostasis in health and disease
Mohammed Shawkat Razzaque
- No. of pages:
- © Elsevier 2021
- 1st April 2021
- Paperback ISBN:
Dr. Faul earned his PhD title at the Albert Einstein College of Medicine in the Bronx in 2005, and conducted his postdoctoral research training at the Mount Sinai School of Medicine in New York City. He currently is an Associate Professor in the Division of Nephrology within the Department of Medicine and in the Department of Cell, Developmental and Integrative Biology (CDIB) at UAB.) He is also a member of the Comprehensive Diabetes Center and Section of Cardio-Renal Physiology and Medicine. He focuses on circulating fibroblast growth factors and their pathological effects on the heart in the context of diabetes and chronic kidney disease. In collaborations with pharma industry, Dr. Faul analyzes beneficial cardiac effects of pharmacological blockers for fibroblast growth factor receptors in animal models with diabetes and kidney injury. Dr. Faul received research funding from the American Diabetes Association (ADA), the American Society of Nephrology (ASN), and American Heart Association (AHA), and the NephCure Foundation, as well as support from pharma industry.
Associate Professor of Medicine, Department of Medicine, Division of Nephrology, The University of Alabama at Birmingham, Birmingham, AL, USA
Dr. White studied the molecular genetics of metabolic bone diseases during an NIH-sponsored postdoctoral fellowship at the Indiana University School of Medicine (IUSM). He played an instrumental role in discovering the novel hormone FGF23 during this time, and since then his laboratory has been funded to study FGF23 and its co-receptor Klotho. Within the University, he is Director of the MMGE Division of Molecular Genetics and Gene Therapy and currently a member of the Indiana Center for Musculoskeletal Health (ICMH).
Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN, USA
Dr. Gutiérrez is the Hilda B. Anderson Endowed Chair in Nephrology, Professor of Medicine and Epidemiology, Associate Director of the Division of Nephrology, and Deputy Director of the Center for Clinical and Translational Science at the University of Alabama at Birmingham (UAB). Dr. Gutiérrez’s research is focused on understanding pathophysiological mechanisms underlying disorders of phosphorus and vitamin D metabolism in health and in individuals with kidney disease. He has a special interest in delineating environmental and/or behavioral factors that may modulate these associations, particularly those related to health disparities, poverty and nutrition. To this end, his group conducts epidemiologic and patient-oriented studies investigating the impact of disturbances in phosphorus metabolism on kidney and cardiovascular health. He is funded by grants from the National Institutes of Health, the American Heart Association, and industry.
Hilda B. Anderson Endowed Chair in Nephrology, Professor of Medicine and Epidemiology, Associate Director of the Division of Nephrology, and Deputy Director of the Center for Clinical and Translational Science, University of Alabama at Birmingham, USA
Elsevier.com visitor survey
We are always looking for ways to improve customer experience on Elsevier.com.
We would like to ask you for a moment of your time to fill in a short questionnaire, at the end of your visit.
If you decide to participate, a new browser tab will open so you can complete the survey after you have completed your visit to this website.
Thanks in advance for your time.